Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a biopharmaceutical company headquartered in Edison, New Jersey. Founded in 2013, the company focuses on developing advanced drug therapies for chronic liver diseases. Hepion's core mission is to enhance treatment options for liver conditions such as non-alcoholic steatohepatitis (NASH), viral hepatitis, and hepatocellular carcinoma (HCC).
The company's flagship product is Rencofilstat, a pan-cyclophilin inhibitor designed to target multiple pathological pathways involved in liver disease progression. This pleiotropic drug therapy has shown promising results in preclinical and clinical trials, including recently completed Phase I trials. Rencofilstat is currently being studied for its potential to address complex liver pathologies, including fibrosis and cancerous conditions associated with NASH and hepatitis.
Another significant development from Hepion is Tenofovir Exalidex, a lipid acyclic nucleoside phosphonate intended to deliver high intracellular concentrations of tenofovir diphosphate, an active antiviral agent. This drug aims to offer more effective treatment options for Hepatitis B patients.
Hepion Pharmaceuticals has also made headlines with its adoption of artificial intelligence (AI)-driven drug development, focusing on precision medicine for chronic diseases. Recent research has revealed that Rencofilstat may exert anti-cancer activity through mechanisms such as altering DNA accessibility, silencing oncogenes, and activating tumor suppressor genes.
The company was formerly known as ContraVir Pharmaceuticals, Inc. before rebranding to Hepion Pharmaceuticals in July 2019 to better align with its focus on liver disease therapies. With a commitment to cutting-edge research and development, Hepion Pharmaceuticals continues to advance its clinical programs and partnerships, offering hope to patients suffering from debilitating liver diseases.
FAQ
What is the current stock price of Hepion Pharmaceuticals (HEPA)?
What is the market cap of Hepion Pharmaceuticals (HEPA)?
What is the main focus of Hepion Pharmaceuticals?
What is Rencofilstat?
What other products is Hepion Pharmaceuticals developing?
Where is Hepion Pharmaceuticals headquartered?
When was Hepion Pharmaceuticals founded?
Has Rencofilstat completed any clinical trials?
Does Hepion Pharmaceuticals use any advanced technologies in its research?
What was the former name of Hepion Pharmaceuticals?
Why did the company change its name?
Is Hepion Pharmaceuticals involved in any partnerships?
